Market cap
$45 Mln
Recently Viewed
Clear All$0.30
$0.00 (0.00%)As on 27-Jul-2023 09:30EDT
Market cap
$45 Mln
Revenue (TTM)
$10 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-157 Mln
ROE
-3.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.8
Debt to Equity
0.5
Book Value
$--
EPS
$-1.2
Face value
--
Shares outstanding
151,680,992
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Greenlight Biosciences Holdings PBC (GRNA)
| -74.6 | 1.2 | -6.1 | -85.2 | -- | -- | -- |
|
BSE Sensex*
| -8.4 | 0.0 | -7.2 | 5.0 | 9.0 | 9.4 | 12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Greenlight Biosciences Holdings PBC (GRNA)
|
0.3 | 45.4 | 10.2 | -158.1 | -1,523.2 | -299.1 | -- | 2.1 |
| 66.2 | 8,558.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 38.2 | 15.0 | |
| 64.6 | 7,998.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.5 | |
| 45.4 | 11,791.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 15.8 | 5.3 | |
| 87.2 | 11,760.7 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 67.1 | 7,473.4 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.6 | 156.5 | |
| 524.3 | 12,247.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 20.8 | |
| 501.5 | 14,077.1 | 2,530.2 | 451.1 | 21.3 | 70.2 | 32.5 | 30.8 | |
| 104.6 | 8,153.4 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 320.2 | 8,644.3 | 0.0 | -303.3 | -- | -45.8 | -- | 10.1 |
GreenLight Biosciences Holdings operates as a pre-commercial stage biotechnology company in the United States of America. It provides cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of... high-performing products to promote healthier plants, foods, and people. The company's plant and animal health pipeline includes Calantha for the Colorado potato beetle; Varroa mites, an RNA-based syrup that targets reproductive mites; Vegetable Caterpillar Complex, an dsRNA-based pesticide for the Diamond Back Moth; and Spider Mite Complex for the control of Tetranychus urticae. It also developing fungicides program for botrytis, fusarium, powdery mildew, downy mildew, Asian soybean rust, and rice blast; Gray Mold + for botrytis cinerea; Powdery mildew complex for the control of powdery mildew, caused by Erysiphe necator; and Mycotoxin control for Fusarium Head Blight, a cereal crop based diseases. In addition, the company also developing human health program comprising a phase I/II preclinical stage vaccine for COVID-19; and candidate selection vaccines for Shingles, and oncology. GreenLight Biosciences Holdings was formerly known as Environmental Impact Acquisition Corp. The company was founded in 2008 and is headquartered in Medford, Massachusetts. Read more
Co-Founder, Pres, CEO & Director
Dr. Andrey Juan Zarur Ph.D.
Co-Founder, Pres, CEO & Director
Dr. Andrey Juan Zarur Ph.D.
Headquarters
Medford, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Greenlight Biosciences Holdings PBC (GRNA) is $0.30 (NASDAQ) as of 27-Jul-2023 09:30 EDT. Greenlight Biosciences Holdings PBC (GRNA) has given a return of -85.25% in the last 1 years.
Since, TTM earnings of Greenlight Biosciences Holdings PBC (GRNA) is negative, P/E ratio is not available.
The P/B ratio of Greenlight Biosciences Holdings PBC (GRNA) is 2.14 times as on 27-Jul-2023, a 49 discount to its peers’ median range of 4.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.93
|
3.24
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
-0.93
|
3.24
|
The 52-week high and low of Greenlight Biosciences Holdings PBC (GRNA) are Rs -- and Rs -- as of 10-Apr-2026.
Greenlight Biosciences Holdings PBC (GRNA) has a market capitalisation of $ 45 Mln as on 27-Jul-2023. As per SEBI classification, it is a company.
Before investing in Greenlight Biosciences Holdings PBC (GRNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.